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Abstract
Background: As the most abundant excitatory neurotransmitter in the central nervous system, glutamate has been
accepted to play a major role in the pathophysiology of migraine. The previous studies have reported the glutamate
receptor ionotropic GRIA1 and GRIA3 genes variants associated with migraine. The project aims to investigate the
polymorphisms in both genes for their association with migraine in the Chinese Han population.
Methods: A Han-Chinese case-control population, including 331 unrelated female migraine patients and 330
matched controls, was studied. Variants in genes (GRIA1 and GRIA3) were genotyped by Multiplex SNaPshot assay.
Results: In the group of patients, the frequency of allele C was 84.1 % (557 C alleles) and allele T was 15.9 %
(105 T alleles) for the GRIA1 (rs2195450) in migraineurs, this was significantly as compared with the controls
(P = .001, OR = 1.786, 95 % CI: 1.28–2.49). And an association was also seen in the migraine with aura (MA)
subtype (P = .012, OR = 2.092, 95 % CI: 1.17–3.76) and migraine without aura (MO) subtype (P = .002, OR = 1.737,
95 % CI: 1.23–2.45). However, no evidence was found that GRIA1 (rs548294) or GRIA3 (rs3761555) is associated
with migraine.
Conclusion: Our data of this study confirmed the association of GRIA1 (rs2195450) to female migraine (MA, MO)
susceptibility in the Chinese Han population. The result provides evidence that the glutamatergic system is
implicated in the pathophysiology of migraine.
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Background
Migraine, characterized by recurrent attacks of severe
headache, is a complex debilitating neurovascular dis-
order accompanying with nausea, vomiting, photophobia
and phonophobia, which can cause temporary incapaci-
tation in the migraineur. It is divided into two common
forms: migraine with/or without aura (MA and MO),
and diagnosed according the ICHD-III(HIS 2013) [1].
Epidemiological studies have shown that migraine preva-
lence accounts for 12 % in Caucasian populations [2]
and 9.3 % in mainland of China [3]. With severe influ-
ence on the patient’s physical and mental health, and
even their normal social function, this disorder is
seemed as a heavy burden for patents.
The exact causes and pathophysiological mechanisms
that underlie migraine is elusive. It is generally consid-
ered to be associated with the genetic factors, about
50 % of affected individuals have a first-degree relative
also suffering from migraine [4], with family and twin
studies reporting heritability estimates from 34 to 57 %
[5]. Current research suggests that the trigeminovascular
system also plays an important role in migraine [6, 7],
and neurotransmitters in this system include: serotonin,
dopamine and glutamate implicated in migraine patho-
genesis. The implication of glutamate in trigeminovascu-
lar activation, central sensitization and cortical spreading
depression(CSD) [8–10] as well as the assessment of glu-
tamate concentration in plasma, platelets and cerebro-
spinal fluid in clinical studies [11] argue for a significant
role of the glutamatergic neurotransmission in the
pathophysiology of migraine. Genetic association studies
have mostly investigated variants in serotonin and dopa-
mine receptor genes. Nevertheless, fewer studies have
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been done in relation to the genetics of the Glutamater-
gic system in migraine [12]. The study by Formicola et
al. [13] who found a positive association with 2 SNPs in
GRIA1 and 1 SNP in the GRIA3 in an Italian population
of 250 migraineurs and 260 controls [13]. Recently,
genome-wide association studies (GWAS) also support a
correlation between migraine and variants in glutamater-
gic system genes [14–16].
However, involved in regulating neuronal glutamate
signals lipoprotein receptor LRP1 (rs11172113) gene
variation, the gene mutation of LRP1 has not been found
in the Han population-based study [17]. Therefore, fur-
ther research into the glutamate system is necessary to
ascertain the gene variation in Han-population. There-
fore, to determine if these variations in the GRIA1 and
GRIA3 genes contribute to migraine susceptibility in an
Chinese Han population case-control cohort, we report
the findings of our association study of the 3 SNPs with
a large sample involving 661 female individuals from
southern Fujian province of China.
Methods
Subjects
Based on previous experience our study involves a rela-
tively larger sample size. The study group comprised 331
Han-Chinese female migraine patients from outpatient of
the Department of Neurology at the First Affiliated Hos-
pital of Xiamen University during the period between
September 2013 and May 2015. All of the migraine pa-
tients were diagnosed as having either migraine with
(MA) or migraine without (MO) aura, by two headache
specialists after neurological examination, direct interview,
computed tomography (CT), or magnetic resonance im-
aging (MRI), according to the diagnostic criteria set by the
International Headache Society (international classifica-
tion of headache disorders,3rd edition, 2013) [1]. The con-
trol group comprised 330 non-headache healthy female
volunteers, who were recruited from the same regional
background (southern Fujian province), and matched
for age and gender with the study group. Familial
Hemiplegic Migraine, tumor, depression and other co-
morbid psychiatric disorders were excluded from the
study. The Ethics Committee of the First Affiliated
Hospital of Xiamen University approved this study, and
informed consent was obtained from all participants
and volunteers.
Genetic analysis
Genomic DNA from each participant was extracted from
peripheral blood with ethylene diamine tetraacetic acid
(EDTA) anticoagulant. Genomic DNA was prepared by a
standard extraction method using the QiaAmp DNA Mini
Kit (Qiagen, Hilden, Germany) and the DNA samples
were stored at −20 °C before being used. The three SNPs
were selected for this study rs548294 and rs2195450 in
GRIA1, rs3761555 in GRIA3 were genotyped using Multi-
plex SNaPshot technique (Applied Biosystems by Life
Technologies, Foster City, CA, USA). Table 1 shows the
primers of PCR and SNaPshot reaction. PCR reactions
containing 25 μl final volume mixture (50 mM MgCl2,
10 mM dNTP, 1 μM primers, 5 units Platinum Taq DNA
polymerase). The PCR conditions used were: 95 °C de-
naturation for 2 min, amplification reaction for 33 cycles
(95 °C for 20s, 55 °C for 20s, 72 °C for 40s), with a final
extension step of 72 °C for 5 min. The PCR products were
examined on a 1.5 % agarose gel whose fragments indicate
successful experiment. SNaPshot reaction contains 5 μl
final volume mixture (Reaction mix 2.5 μl, PCR products
1.5 μl, Probe Mix 1.0 μl). SNaPshot reaction procedure is
as following: amplification reaction for 25 cycles (96 °C for
10s, 50 °C for 5 s, 60 °C for 30s), with a final extension
step of 60 °C for 1 min. DNA sequencing: a 10 μl final
volume mixture (SNaPshot purified product 1 μl, Form-
amide Deionized 8.5 μl, GeneScan-120 LIZ Size Standard
0.5 μl). 95 °C denaturation 5 min, and sequenced using an
ABI PRISM 3730 DNA Sequencer (Applied Biosystems by
Life Technologies, Foster City, CA, USA). All sequence
analyses were performed using it’s own DNA Sequencing
Analysis software, GeneMapper4.0.
Statistical analysis
To assess the deviation of each polymorphism from the
Hardy-Weinberg equilibrium (HWE), the public statis-
tics web tool (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl) was
employed. All statistical analyses were performed using
the statistical package SPSS version 20.0 for Windows
(SPSS, Inc., Chicago, IL, USA). The Chi-squared test or t-
test was used to compare age and sex among the groups,
allele and genotype frequencies were compared using the
Chi-squared test. P values were adjusted for multiple
testing using the Bonferroni correction, therefore, we
used P < .05/3 ≈ .017 as a threshold for significance.





GRIA1 Forward 297bp CACCCCAAGTTTTCACTGCT
rs548294 Reverse 297bp GAACCTAAAAGATCCCCAGGT
Probe 63bp 37Ts+CTTAACTCTTAGGCTCTAATA
GRIA1 Forward 259bp GCTGGAGGAGTCCAGAACAG
rs2195450 Reverse 259bp TGCTTGGTAGATGGTGCTTG
Probe 70bp 45Ts+CCCCTCACTCCTTCTTCT
GRIA3 Forward 373bp TGCCAGTGTAAAGCGAACTG
rs3761555 Reverse 373bp GGGGATGACCAACCTTACCT
Probe 56bp 35Ts+TTCAAAATGGAGACAAAAGAT
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Results
General information
This study involved a total of 331 female migraine patients
and 330 female controls. The mean age of the migraine pa-
tients was 35.0 ± 7.6 years, and the controls were 34.4 ±
7.2 years. The migraine patients and the controls were
matched with respect to age and gender (P = .255/1.00).
There are 47 MA and 284 MO included in the migraine
patients group. Two SNPs (rs548294 and rs2195450) in the
GRIA1 gene and one SNP (rs3761555) in the GRIA3 gene
that have previously demonstrated positive association to
migraine in the study by Formicola et al. were selected and
tested in our study [13]. All the genotypic distributions ana-
lyzed in patients and controls were in accordance with the
Hardy-Weinberg equilibrium (P > .05).
GRIA1 polymorphisms
No significant difference in genotypic and allelic distri-
bution was observed in the polymorphisms of rs548294
between migraine cases and controls. And also, differ-
ence was not observed for any of the migraine subtypes
(MA, MO) tested (Tables 2 and 3).
The frequencies of the genotypes of the SNP rs2195450
marker showed significant difference between migraine
cases and controls (P = .004), and also a positive association
with the allelic distribution was observed with an overrep-
resentation of the T allele (Tables 2 and 3). In the group of
patients, the frequency of allele C was 84.1 % (557 C al-
leles) and allele T was 15.9 % (105 T alleles) for the GRIA1 (rs2195450) in migraineurs, this was significantly as com-
pared with the controls (P = .001, OR = 1.786, 95 % CI:
1.28–2.49). And an association was also seen in the MA
subtype (P = .012, OR = 2.092, 95 % CI: 1.17–3.76) and
MO subtype (P = .002, OR = 1.737, 95 % CI: 1.23–2.45).
GRIA3 polymorphisms
No significant difference in genotypic and allelic distribu-
tion was observed in the polymorphisms of rs3761555
between migraine cases and controls. And also, difference
was not observed for any of the tow migraine subtypes
tested (Tables 2 and 3).
Discussion
Glutamate is the most abundant excitatory neurotrans-
mitter in the brain,glutamate and the receptors are in-
timately involved in trigeminovascular activation, central
sensitization and cortical spreading depression. Alter-
ations in the function or expression of components of
this system may be involved in migraine susceptibility
[12]. Biochemical, preclinical experiments and pharma-
cological studies also support involvement of glutamate
in migraine [18–20].
In addition, the previous studies have reported the sig-
nificant role of glutamatergic gene variants played in the
pathophysiology of migraine. GWAS supported that
Table 2 Genotype frequencies of gene polymorphism in Chinese
population
Gene SNP Group Genotype n(%) P
GRIA1 rs548294 GG GA AA
Migraine 159(48.0) 130(39.3) 42(12.7) .642
MA 28(59.6) 16(34.0) 3(6.4) .280
MO 131(46.1) 114(40.1) 39(13.7) .494
Control 157(47.6) 138(41.8) 35(10.6)
rs2195450 CC CT TT
Migraine 238(71.9) 81(24.5) 12(3.6) .004*
MA 31(66.0) 15(31.9) 1(2.1) .027
MO 207(72.9) 66(23.2) 11(3.9) .011**
Control 272(82.4) 53(16.1) 5(1.5)
GRIA3 rs3761555 GG GA AA
Migraine 135(40.8) 154(46.5) 42(12.7) .564
MA 21(44.7) 19(40.4) 7(14.9) .864
MO 114(40.1) 135(47.5) 35(12.3) .470
Control 134(40.6) 145(43.9) 51(15.5)
Abbreviations: MA migraine with aura, MO migraine without aura, SNP single
nucleotide polymorphisms
*All female migraine patients compared with controls by genotype: P < .017
**MO compared with controls by genotype: P < .017
Table 3 Allele frequencies of gene polymorphism in Chinese
population
Gene SNP Group Allele n(%) P
GRIA1 rs548294 G A
Migraine 448(67.7) 214(32.3) .752
MA 72(76.6) 22(23.4) .110
MO 376(66.2) 192(33.8) .394
Control 452(68.5) 208(31.5)
rs2195450 C T
Migraine 557(84.1) 105(15.9) .001*
MA 77(81.9) 17(18.1) .012**
MO 480(84.5) 88(15.5) .002***
Control 597(90.5) 63(9.5)
GRIA3 rs3761555 G A
Migraine 424(64.0) 238(36.0) .579
MA 61(64.9) 33(35.1) .663
MO 363(63.9) 205(36.1) .629
Control 413(62.5) 247(37.4)
Abbreviations: MA migraine with aura, MO migraine without aura, SNP single
nucleotide polymorphisms, CI confidence interval
*All female migraine patients compared with controls by allele: odds ratio =1.786,
95 % CI: 1.28–2.49, P < .017
**MA compared with controls by allele: odds ratio =2.092, 95 % CI: 1.17–3.76,
P < .017
***MO compared with controls by allele: odds ratio =1.737, 95 % CI: 1.23–2.45,
P < .017
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genetic variants (rs1835740 at 8q22.1 and rs11172113 in
LRP1)associated with migraine [16, 21, 22], and both of
these tow genetic variants were involved in the regula-
tion of glutamatergic system [23]. Another association
analysis on Italian population have reported two genes
that code for subunits of the ionotropic AMPA receptors
GRIA1 and GRIA3 have been implicated in migraine
[13]. Although a number of studies have reported associ-
ations between particular glutamatergic gene variants
and migraine susceptibility, replication studies to con-
firm previous findings are generally lacking [24]. For in-
stance, as for the LRP1 gene variation, our previous
results [17] and another research-based Chinese Han
population [25] both failed to replicate the association
between rs11172113 and migraine. The present study is
the first reported case-control association study to inde-
pendently replicate the variations in the GRIA1 and
GRIA3 genes in Chinese Han population.
In our present study, a statistically significant finding
is that the GRIA1 rs2195450 variant is a potential gen-
etic risk factor for female migraine in the Chinese Han
population from the southern Fujian province of China.
In the subgroup analysis, the variant indicates associ-
ation with the MA, MO subtype. This result was not as
same as the previous reports. In 2010, Formicola and col-
leagues first reported the rs2195450 SNP of GRIA1 gene
was associated with the MA subgroup of migraineurs in
Italian Caucasian population [13]. However, the SNP
rs2195450 was in Hardy-Weinberg disequilibrium (DHW)
both in controls and in patients, suggesting the possibility
in the study of inappropriate population stratification and
selection or other confounding factors.
Subsequently, two independent studies in Australia [26]
and Italy Caucasian population [27] have both failed to
identify the association of rs2195450 with migraine, either
MA or MO. But it should be noted that the study in
Australia population, the rs2195450 SNP was in DHW in
the control group, and the study in Italy Caucasian popu-
lation only included 186 patients. Compared with previ-
ous studies, our study involves a relatively larger
sample size. Moreover, the rs2195450 SNP was found
in HWE both in controls and in patients. Nonetheless,
an even larger scale case-control study in populations
of different origin should be performed to evaluate the
association of the GRIA1 rs2195450 variant to migraine
susceptibility.
However, no association of the other SNP (rs548294) of
GRIA1 gene with migraine was found in our study, even in
the subtype’s analysis. Although the previous results mani-
fests that rs548294 SNP was significantly associated with
migraine (MO and Female) in Italian Caucasian population
[13]. But subsequent replication studies of this variant car-
ried out in Italian Caucasian population failed to identify
the association of rs548294 with migraine. Furthermore,
when the two Italian Caucasian population studies were
combined for pooled analysis, none of the genetic models
testes provided a significant association between rs548294
polymorphism and MO risk [27]. In addition, another
study in Australia population reported no evidence of asso-
ciation between rs548294 and risk of migraine [26]. Exist-
ing studies indicates that this variant may be not a risk
factor for migraine.
Similarly, the rs3761555 SNP of GRIA3 gene was also
found no association with MA or MO in our study. This
result was opposite to the previous two findings. The
two former studies have showed the same results that
rs3761555 SNP was significantly associated with mi-
graine (MA and Female) [26, 27]. These controversial re-
sults may be caused by ethnic differences, environmental
effects, and limited sample size.
Conclusions
This study is the first report of rs2195450 SNP in GRIA1
gene associated with female migraine (MA, MO) in
Chinese Han population. The result also provides evi-
dence that the glutamatergic system, particularly the GRIA1
gene, is implicated in the pathophysiology of migraine. Fur-
ther research into the glutamatergic system is necessary to
ascertain the mechanism in the aetiology of migraine.
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